A hepatitis B virus nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotrans
Usage/Dosage
-Administered on an empty stomach (at least 2 hours after a meal
and 2 hours before the next meal).
-0.5 mg once daily
-In adults and adolescents (at least 16 years
of age) with a history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance substitutions : 1mg once daily.
